FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034229498> ?p ?o ?g. }

• W3034229498 endingPage "575" @default.
• W3034229498 startingPage "570" @default.
• W3034229498 abstract "Abstract Objective To investigate the efficacy and safety of pembrolizumab in women with recurrent small cell neuroendocrine tumors of the lower genital tract. Methods We conducted an open-label, investigator-initiated phase II basket trial of pembrolizumab 200 mg intravenously every 3 weeks in patients with rare tumors ( ClinicalTrials.gov : NCT02721732 ). The trial had prespecified cohorts, including small cell malignancies of extrapulmonary origin. Eligibility criteria included disease progression during standard treatment in the 6 months before study enrollment. Patients were enrolled from February 2017 to February 2019. The primary endpoint was the proportion of patients alive without progression at 27 weeks. Response to pembrolizumab was evaluated every 9 weeks (3 cycles) with radiographic imaging. Results Seven women with gynecologic extrapulmonary small cell carcinoma were enrolled, 6 with cervical and 1 with vulvar carcinoma. No patient was progression free at 27 weeks. At first radiologic assessment, 1 patient had stable disease, while 6 had progression. The single patient with stable disease at 6 weeks had disease progression at 14 weeks. The median progression-free interval was 2.1 months (range 0.8–3.3 months). Severe treatment-related adverse events (≥grade 3) were seen in 2 of 7 patients (29%); 1 patient had grade 3 asymptomatic elevation of serum alkaline phosphatase, and 1 had grade 3 asymptomatic elevation of serum alanine aminotransferase. Conclusions Pembrolizumab alone showed minimal activity in women with recurrent small cell neuroendocrine tumors of the lower genital tract. Treatment was well tolerated in the majority of study participants, and the rate of severe adverse events was low." @default.
• W3034229498 created "2020-06-19" @default.
• W3034229498 creator A5000158770 @default.
• W3034229498 creator A5005436649 @default.
• W3034229498 creator A5008786567 @default.
• W3034229498 creator A5026269100 @default.
• W3034229498 creator A5033972077 @default.
• W3034229498 creator A5062925555 @default.
• W3034229498 creator A5068368047 @default.
• W3034229498 creator A5068495463 @default.
• W3034229498 creator A5070385327 @default.
• W3034229498 creator A5082358197 @default.
• W3034229498 creator A5089393952 @default.
• W3034229498 date "2020-09-01" @default.
• W3034229498 modified "2023-09-29" @default.
• W3034229498 title "Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract" @default.
• W3034229498 cites W1966261847 @default.
• W3034229498 cites W1970081245 @default.
• W3034229498 cites W2011458181 @default.
• W3034229498 cites W2037046556 @default.
• W3034229498 cites W2104885590 @default.
• W3034229498 cites W2137535143 @default.
• W3034229498 cites W2418354692 @default.
• W3034229498 cites W2546669363 @default.
• W3034229498 cites W2583304018 @default.
• W3034229498 cites W2587333476 @default.
• W3034229498 cites W2594200836 @default.
• W3034229498 cites W2635951006 @default.
• W3034229498 cites W2745840031 @default.
• W3034229498 cites W2799753303 @default.
• W3034229498 cites W2887004395 @default.
• W3034229498 cites W2909503380 @default.
• W3034229498 cites W2925815206 @default.
• W3034229498 cites W2972117663 @default.
• W3034229498 cites W3000736809 @default.
• W3034229498 cites W3006702732 @default.
• W3034229498 cites W3010680101 @default.
• W3034229498 cites W4294309286 @default.
• W3034229498 doi "https://doi.org/10.1016/j.ygyno.2020.05.682" @default.
• W3034229498 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7486997" @default.
• W3034229498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32534809" @default.
• W3034229498 hasPublicationYear "2020" @default.
• W3034229498 type Work @default.
• W3034229498 sameAs 3034229498 @default.
• W3034229498 citedByCount "39" @default.
• W3034229498 countsByYear W30342294982020 @default.
• W3034229498 countsByYear W30342294982021 @default.
• W3034229498 countsByYear W30342294982022 @default.
• W3034229498 countsByYear W30342294982023 @default.
• W3034229498 crossrefType "journal-article" @default.
• W3034229498 hasAuthorship W3034229498A5000158770 @default.
• W3034229498 hasAuthorship W3034229498A5005436649 @default.
• W3034229498 hasAuthorship W3034229498A5008786567 @default.
• W3034229498 hasAuthorship W3034229498A5026269100 @default.
• W3034229498 hasAuthorship W3034229498A5033972077 @default.
• W3034229498 hasAuthorship W3034229498A5062925555 @default.
• W3034229498 hasAuthorship W3034229498A5068368047 @default.
• W3034229498 hasAuthorship W3034229498A5068495463 @default.
• W3034229498 hasAuthorship W3034229498A5070385327 @default.
• W3034229498 hasAuthorship W3034229498A5082358197 @default.
• W3034229498 hasAuthorship W3034229498A5089393952 @default.
• W3034229498 hasBestOaLocation W30342294982 @default.
• W3034229498 hasConcept C121608353 @default.
• W3034229498 hasConcept C126322002 @default.
• W3034229498 hasConcept C143998085 @default.
• W3034229498 hasConcept C2777546739 @default.
• W3034229498 hasConcept C2777701055 @default.
• W3034229498 hasConcept C2780057760 @default.
• W3034229498 hasConcept C29456083 @default.
• W3034229498 hasConcept C2991749049 @default.
• W3034229498 hasConcept C3018711458 @default.
• W3034229498 hasConcept C42407357 @default.
• W3034229498 hasConcept C71924100 @default.
• W3034229498 hasConceptScore W3034229498C121608353 @default.
• W3034229498 hasConceptScore W3034229498C126322002 @default.
• W3034229498 hasConceptScore W3034229498C143998085 @default.
• W3034229498 hasConceptScore W3034229498C2777546739 @default.
• W3034229498 hasConceptScore W3034229498C2777701055 @default.
• W3034229498 hasConceptScore W3034229498C2780057760 @default.
• W3034229498 hasConceptScore W3034229498C29456083 @default.
• W3034229498 hasConceptScore W3034229498C2991749049 @default.
• W3034229498 hasConceptScore W3034229498C3018711458 @default.
• W3034229498 hasConceptScore W3034229498C42407357 @default.
• W3034229498 hasConceptScore W3034229498C71924100 @default.
• W3034229498 hasFunder F4320337351 @default.
• W3034229498 hasIssue "3" @default.
• W3034229498 hasLocation W30342294981 @default.
• W3034229498 hasLocation W30342294982 @default.
• W3034229498 hasOpenAccess W3034229498 @default.
• W3034229498 hasPrimaryLocation W30342294981 @default.
• W3034229498 hasRelatedWork W1612598408 @default.
• W3034229498 hasRelatedWork W198966119 @default.
• W3034229498 hasRelatedWork W1991882263 @default.
• W3034229498 hasRelatedWork W2062982952 @default.
• W3034229498 hasRelatedWork W2409420392 @default.
• W3034229498 hasRelatedWork W2414165388 @default.
• W3034229498 hasRelatedWork W2526660126 @default.
• W3034229498 hasRelatedWork W2792600153 @default.

• next